Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas

Chinese Journal of Cancer Research

Volumn 28, Issue 1, 2016, Pages 29-49

  Rao, Qiu ^a   Xia, Qiu Yuan ^a   Cheng, Liang ^b   Zhou, Xiao Jun ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immunohistochemistry; Molecular genetics; Renal cell carcinoma (RCC); Renal tumor

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; MEMBRANE PROTEIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; SUCCINATE DEHYDROGENASE; UNCLASSIFIED DRUG; XP11 PROTEIN;

AUTOSOMAL DOMINANT DISORDER; BENIGN TUMOR; CELL DIFFERENTIATION; CLEAR CELL TUBULOPAPILLARY RENAL CELL CARCINOMA; END STAGE RENAL DISEASE; GENE TRANSLOCATION; HEREDITARY LEIOMYOMATOSIS RENAL CELL CARCINOMA; HUMAN; HYBRID ONCOCYTIC CHROMOPHOBE TUMOR; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUMOR; MEDICAL LITERATURE; MELANOCYTE; MOLECULAR GENETICS; MORPHOLOGY; REVIEW; THYROID CELL; TUBULOCYSTIC RENAL CELL CARCINOMA;

EID: 84959571847     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.3978/j.issn.1000-9604.2016.01.03     Document Type: Review

References (173)

1. Tickoo SK, dePeralta-Venturina MN, Harik LR, et al. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol 2006;30:141-53.
2. Gobbo S, Eble JN, Grignon DJ, et al. Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am J Surg Pathol 2008;32:1239-45.
3. Aydin H, Chen L, Cheng L, et al. Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney. Am J Surg Pathol 2010;34:1608-21.
4. Adam J, Couturier J, Molinie V, et al. Clear-cell papillary renal cell carcinoma: 24 cases of a distinct low-grade renal tumour and a comparative genomic hybridization array study of seven cases. Histopathology 2011;58:1064-71.
5. Rohan SM, Xiao Y, Liang Y, et al. Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins. Mod Pathol 2011;24:1207-20.
6. Williamson SR, Eble JN, Cheng L, et al. Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile. Mod Pathol 2013;26:697-708.
7. Shi SS, Shen Q, Xia QY, et al. Clear cell papillary renal cell carcinoma: a clinicopathological study emphasizing ultrastructural features and cytogenetic heterogeneity. Int J Clin Exp Pathol 2013;6:2936-42.
8. Williamson SR, Gupta NS, Eble JN, et al. Clear Cell Renal Cell Carcinoma With Borderline Features of Clear Cell Papillary Renal Cell Carcinoma: Combined Morphologic, Immunohistochemical, and Cytogenetic Analysis. Am J Surg Pathol 2015;39:1502-10.
9. Aron M, Chang E, Herrera L, et al. Clear cell-papillary renal cell carcinoma of the kidney not associated with end-stage renal disease: clinicopathologic correlation with expanded immunophenotypic and molecular characterization of a large cohort with emphasis on relationship with renal angiomyoadenomatous tumor. Am J Surg Pathol 2015;39:873-88.
10. Deml KF, Schildhaus HU, Comperat E, et al. Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell carcinoma. Am J Surg Pathol 2015;39:889-901.
11. Michal M, Hes O, Havlicek F. Benign renal angiomyoadenomatous tumor: a previously unreported renal tumor. Ann Diagn Pathol 2000;4:311-5.
12. Williamson SR, Zhang S, Eble JN, et al. Clear cell papillary renal cell carcinoma-like tumors in patients with von Hippel-Lindau disease are unrelated to sporadic clear cell papillary renal cell carcinoma. Am J Surg Pathol 2013;37:1131-9.
13. Zhou H, Zheng S, Truong LD, et al. Clear cell papillary renal cell carcinoma is the fourth most common histologic type of renal cell carcinoma in 290 consecutive nephrectomies for renal cell carcinoma. Hum Pathol 2014;45:59-64.
14. Rao P, Monzon F, Jonasch E, et al. Clear cell papillary renal cell carcinoma in patients with von Hippel-Lindau syndrome--clinicopathological features and comparative genomic analysis of 3 cases. Hum Pathol 2014;45:1966-72.
15. Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol 2013;37:1469-89.
16. Leroy X, Camparo P, Gnemmi V, et al. Clear cell papillary renal cell carcinoma is an indolent and low-grade neoplasm with overexpression of cyclin-D1. Histopathology 2014;64:1032-6.
17. Munari E, Marchionni L, Chitre A, et al. Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Hum Pathol 2014;45:1130-8.
18. Slaby O, Redova M, Poprach A, et al. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer 2012;51:707-16.
19. Chan SY, Loscalzo J. MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle 2010;9:1072-83.
20. Chang W, Lee CY, Park JH, et al. Survival of hypoxic human mesenchymal stem cells is enhanced by a positive feedback loop involving miR-210 and hypoxia-inducible factor 1. J Vet Sci 2013;14:69-76.
21. Lawrie CH, Larrea E, Larrinaga G, et al. Targeted next-generation sequencing and non-coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes. J Pathol 2014;232:32-42.
22. Fisher KE, Yin-Goen Q, Alexis D, et al. Gene expression profiling of clear cell papillary renal cell carcinoma: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Mod Pathol 2014;27:222-30.
23. Wolfe A, Dobin SM, Grossmann P, et al. Clonal trisomies 7,10 and 12, normal 3p and absence of VHL gene mutation in a clear cell tubulopapillary carcinoma of the kidney. Virchows Arch 2011;459:457-63.
24. Kuroda N, Shiotsu T, Kawada C, et al. Clear cell papillary renal cell carcinoma and clear cell renal cell carcinoma arising in acquired cystic disease of the kidney: an immunohistochemical and genetic study. Ann Diagn Pathol 2011;15:282-5.
25. Inoue T, Matsuura K, Yoshimoto T, et al. Genomic profiling of renal cell carcinoma in patients with end-stage renal disease. Cancer Sci 2012;103:569-76.
26. Rao Q, Cheng L, Xia QY, et al. Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms (PEComas): a clinicopathological study emphasizing extrarenal PEComas. Histopathology 2013;62:642-50.
27. Argani P, Aulmann S, Illei PB, et al. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol 2010;34:1395-406.
28. Argani P, Olgac S, Tickoo SK, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 2007;31:1149-60.
29. Malouf GG, Su X, Yao H, et al. Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes. Clin Cancer Res 2014;20:4129-40.
30. Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 2007;67:919-29.
31. Medendorp K, van Groningen JJ, Schepens M, et al. Molecular mechanisms underlying the MiT translocation subgroup of renal cell carcinomas. Cytogenet Genome Res 2007;118:157-65.
32. Argani P, Ladanyi M. Translocation carcinomas of the kidney. Clin Lab Med 2005;25:363-78.
33. Delahunt B, Egevad L, Montironi R, et al. International Society of Urological Pathology (ISUP) consensus conference on renal neoplasia: rationale and organization. Am J Surg Pathol 2013;37:1463-8.
34. Komai Y, Fujiwara M, Fujii Y, et al. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res 2009;15:1170-6.
35. Argani P, Lae M, Ballard ET, et al. Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol 2006;24:1529-34.
36. Armah HB, Parwani AV, Surti U, et al. Xp11.2 translocation renal cell carcinoma occurring during pregnancy with a novel translocation involving chromosome 19: a case report with review of the literature. Diagn Pathol 2009;4:15.
37. Nouh MA, Kuroda N, Yamashita M, et al. Renal cell carcinoma in patients with end-stage renal disease: relationship between histological type and duration of dialysis. BJU Int 2010;105:620-7.
38. Geller JI, Argani P, Adeniran A, et al. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer 2008;112:1607-16.
39. Koie T, Yoneyama T, Hashimoto Y, et al. An aggressive course of Xp11 translocation renal cell carcinoma in a 28-year-old man. Int J Urol 2009;16:333-5.
40. Rao Q, Guan B, Zhou XJ. Xp11.2 Translocation renal cell carcinomas have a poorer prognosis than non-Xp11.2 translocation carcinomas in children and young adults: a meta-analysis. Int J Surg Pathol 2010;18:458-64.
41. Rao Q, Chen JY, Wang JD, et al. Renal cell carcinoma in children and young adults: clinicopathological, immunohistochemical, and VHL gene analysis of 46 cases with follow-up. Int J Surg Pathol 2011;19:170-9.
42. Rais-Bahrami S, Drabick JJ, De Marzo AM, et al. Xp11 translocation renal cell carcinoma: delayed but massive and lethal metastases of a chemotherapy-associated secondary malignancy. Urology 2007;70:178.e3-6.
43. Armah HB, Parwani AV. Xp11.2 translocation renal cell carcinoma. Arch Pathol Lab Med 2010;134:124-9.
44. Choueiri TK, Lim ZD, Hirsch MS, et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 2010;116:5219-25.
45. Malouf GG, Camparo P, Oudard S, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol 2010;21:1834-8.
46. Rao Q, Williamson SR, Zhang S, et al. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol 2013;37:804-15.
47. Green WM, Yonescu R, Morsberger L, et al. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service. Am J Surg Pathol 2013;37:1150-63.
48. Martignoni G, Pea M, Gobbo S, et al. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol 2009;22:1016-22.
49. Martignoni G, Gobbo S, Camparo P, et al. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Mod Pathol 2011;24:1313-9.
50. Camparo P, Vasiliu V, Molinie V, et al. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol 2008;32:656-70.
51. Mosquera JM, Dal Cin P, Mertz KD, et al. Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas. Diagn Mol Pathol 2011;20:129-37.
52. Kim SH, Choi Y, Jeong HY, et al. Usefulness of a break-apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma. Virchows Arch 2011;459:299-306.
53. Klatte T, Streubel B, Wrba F, et al. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis. Am J Clin Pathol 2012;137:761-8.
54. Rao Q, Shen Q, Xia QY, et al. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity. Am J Surg Pathol 2015;39:1181-96.
55. Chang IW, Huang HY, Sung MT. Melanotic Xp11 translocation renal cancer: a case with PSF-TFE3 gene fusion and up-regulation of melanogenetic transcripts. Am J Surg Pathol 2009;33:1894-901.
56. Tanaka M, Kato K, Gomi K, et al. Perivascular epithelioid cell tumor with SFPQ/PSF-TFE3 gene fusion in a patient with advanced neuroblastoma. Am J Surg Pathol 2009;33:1416-20.
57. LeGallo RD, Stelow EB, Sukov WR, et al. Melanotic xp11.2 neoplasm of the ovary: report of a unique case. Am J Surg Pathol 2012;36:1410-4.
58. Argani P, Hawkins A, Griffin CA, et al. A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol 2001;158:2089-96.
59. Davis IJ, Hsi BL, Arroyo JD, et al. Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11) (p21;q13) chromosome translocation. Proc Natl Acad Sci U S A 2003;100:6051-6.
60. Kuiper RP, Schepens M, Thijssen J, et al. Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. Hum Mol Genet 2003;12:1661-9.
61. Argani P, Lae M, Hutchinson B, et al. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol 2005;29:230-40.
62. Pecciarini L, Cangi MG, Lo Cunsolo C, et al. Characterization of t(6;11)(p21;q12) in a renal-cell carcinoma of an adult patient. Genes Chromosomes Cancer 2007;46:419-26.
63. Hora M, Hes O, Urge T, et al. A distinctive translocation carcinoma of the kidney [“rosette-like forming,” t(6;11), HMB45-positive renal tumor]. Int Urol Nephrol 2009;41:553-7.
64. Zhan HQ, Wang CF, Zhu XZ, et al. Renal cell carcinoma with t(6;11) translocation: a patient case with a novel Alpha-TFEB fusion point. J Clin Oncol 2010;28:e709-13.
65. Suárez-Vilela D, Izquierdo-García F, Méndez-Álvarez JR, et al. Renal translocation carcinoma with expression of TFEB: presentation of a case with distinctive histological and immunohistochemical features. Int J Surg Pathol 2011;19:506-9.
66. Inamura K, Fujiwara M, Togashi Y, et al. Diverse fusion patterns and heterogeneous clinicopathologic features of renal cell carcinoma with t(6;11) translocation. Am J Surg Pathol 2012;36:35-42.
67. Petersson F, Vanecek T, Michal M, et al. A distinctive translocation carcinoma of the kidney; “rosette forming,” t(6;11), HMB45-positive renal tumor: a histomorphologic, immunohistochemical, ultrastructural, and molecular genetic study of 4 cases. Hum Pathol 2012;43:726-36.
68. Rao Q, Liu B, Cheng L, et al. Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol 2012;36:1327-38.
69. Argani P, Yonescu R, Morsberger L, et al. Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum. Am J Surg Pathol 2012;36:1516-26.
70. Rao Q, Zhang XM, Tu P, et al. Renal cell carcinomas with t(6;11)(p21;q12) presenting with tubulocystic renal cell carcinoma-like features. Int J Clin Exp Pathol 2013;6:1452-7.
71. Smith NE, Illei PB, Allaf M, et al. t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases. Am J Surg Pathol 2014;38:604-14.
72. Barletta JA, Hornick JL. Succinate dehydrogenase-deficient tumors: diagnostic advances and clinical implications. Adv Anat Pathol 2012;19:193-203.
73. Gill AJ. Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. Pathology 2012;44:285-92.
74. Doyle LA, Hornick JL. Gastrointestinal stromal tumours: from KIT to succinate dehydrogenase. Histopathology 2014;64:53-67.
75. Ricketts CJ, Shuch B, Vocke CD, et al. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol 2012;188:2063-71.
76. Vanharanta S, Buchta M, McWhinney SR, et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet 2004;74:153-9.
77. Housley SL, Lindsay RS, Young B, et al. Renal carcinoma with giant mitochondria associated with germ-line mutation and somatic loss of the succinate dehydrogenase B gene. Histopathology 2010;56:405-8.
78. Gill AJ, Pachter NS, Chou A, et al. Renal tumors associated with germline SDHB mutation show distinctive morphology. Am J Surg Pathol 2011;35:1578-85.
79. Miettinen M, Sarlomo-Rikala M, McCue P, et al. Mapping of succinate dehydrogenase losses in 2258 epithelial neoplasms. Appl Immunohistochem Mol Morphol 2014;22:31-6.
80. Gill AJ, Hes O, Papathomas T, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol 2014;38:1588-602.
81. Williamson SR, Eble JN, Amin MB, et al. Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. Mod Pathol 2015;28:80-94.
82. Papathomas TG, Gaal J, Corssmit EP, et al. Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis. Eur J Endocrinol 2014;170:1-12.
83. Yakirevich E, Ali SM, Mega A, et al. A Novel SDHA-deficient Renal Cell Carcinoma Revealed by Comprehensive Genomic Profiling. Am J Surg Pathol 2015;39:858-63.
84. Haller F, Moskalev EA, Faucz FR, et al. Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. Endocr Relat Cancer 2014;21:567-77.
85. Killian JK, Miettinen M, Walker RL, et al. Recurrent epimutation of SDHC in gastrointestinal stromal tumors. Sci Transl Med 2014;6:268ra177.
86. Burnichon N, Briere JJ, Libe R, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 2010;19:3011-20.
87. Fleming S, Mayer NJ, Vlatkovic LJ, et al. Signalling pathways in succinate dehydrogenase B-associated renal carcinoma. Histopathology 2014;64:477-83.
88. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994;263:1281-4.
89. Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997;14:439-49.
90. Lawrence B, Perez-Atayde A, Hibbard MK, et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 2000;157:377-84.
91. Ma Z, Cools J, Marynen P, et al. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 2000;95:2144-9.
92. Bridge JA, Kanamori M, Ma Z, et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 2001;159:411-5.
93. Dirks WG, Fahnrich S, Lis Y, et al. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int J Cancer 2002;100:49-56.
94. Gascoyne RD, Lamant L, Martin-Subero JI, et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood 2003;102:2568-73.
95. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
96. Lin E, Li L, Guan Y, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 2009;7:1466-76.
97. Debelenko LV, Raimondi SC, Daw N, et al. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol 2011;24:430-42.
98. Mariño-Enríquez A, Ou WB, Weldon CB, et al. ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosomes Cancer 2011;50:146-53.
99. Sugawara E, Togashi Y, Kuroda N, et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer 2012;118:4427-36.
100. Sukov WR, Hodge JC, Lohse CM, et al. ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Mod Pathol 2012;25:1516-25.
101. Hodge JC, Pearce KE, Sukov WR. Distinct ALK-rearranged and VCL-negative papillary renal cell carcinoma variant in two adults without sickle cell trait. Mod Pathol 2013;26:604-5.
102. Lee C, Park JW, Suh JH, et al. ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients. Korean J Pathol 2013;47:452-7.
103. Smith NE, Deyrup AT, Marino-Enriquez A, et al. VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy? Am J Surg Pathol 2014;38:858-63.
104. Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008;8:11-23.
105. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
106. Chihara D, Suzuki R. More on crizotinib. N Engl J Med 2011;364:776-7; author reply 8.
107. Sangoi AR, Higgins JP. Bilateral mixed epithelial stromal tumor in an end-stage renal disease patient: the first case report. Hum Pathol 2008;39:142-6.
108. Hamamoto S, Okamura T, Mizuno K, et al. Renal oncocytoma with bilateral synchronous renal cell carcinoma in a patient undergoing long-term hemodialysis. Int J Urol 2008;15:87-9.
109. Sakura M, Masuda H, Saito K, et al. Collecting duct carcinoma with acquired cystic disease of the kidney in a long-term hemodialysis patient. Int J Urol 2008;15:93-5.
110. Nishihara K, Shomori K, Nagashima Y, et al. Chromophobe renal cell carcinoma and 'capsulomas' with acquired cystic disease of the kidney in a long-term hemodialysis patient. Int J Urol 2008;15:543-5.
111. Srigley JR, Delahunt B. Uncommon and recently described renal carcinomas. Mod Pathol 2009;22 Suppl 2:S2-S23.
112. Kuroda N, Tamura M, Hamaguchi N, et al. Acquired cystic disease-associated renal cell carcinoma with sarcomatoid change and rhabdoid features. Ann Diagn Pathol 2011;15:462-6.
113. Sule N, Yakupoglu U, Shen SS, et al. Calcium oxalate deposition in renal cell carcinoma associated with acquired cystic kidney disease: a comprehensive study. Am J Surg Pathol 2005;29:443-51.
114. Cossu-Rocca P, Eble JN, Zhang S, et al. Acquired cystic disease-associated renal tumors: an immunohistochemical and fluorescence in situ hybridization study. Mod Pathol 2006;19:780-7.
115. Pan CC, Chen YJ, Chang LC, et al. Immunohistochemical and molecular genetic profiling of acquired cystic disease-associated renal cell carcinoma. Histopathology 2009;55:145-53.
116. Enoki Y, Katoh G, Okabe H, et al. Clinicopathological features and CD57 expression in renal cell carcinoma in acquired cystic disease of the kidneys: with special emphasis on a relation to the duration of haemodialysis, the degree of calcium oxalate deposition, histological type, and possible tumorigenesis. Histopathology 2010;56:384-94.
117. Kuroda N, Yamashita M, Kakehi Y, et al. Acquired cystic disease-associated renal cell carcinoma: an immunohistochemical and fluorescence in situ hybridization study. Med Mol Morphol 2011;44:228-32.
118. Bhatnagar R, Alexiev BA. Renal-cell carcinomas in end-stage kidneys: a clinicopathological study with emphasis on clear-cell papillary renal-cell carcinoma and acquired cystic kidney disease-associated carcinoma. Int J Surg Pathol 2012;20:19-28.
119. Ahn S, Kwon GY, Cho YM, et al. Acquired cystic disease-associated renal cell carcinoma: further characterization of the morphologic and immunopathologic features. Med Mol Morphol 2013;46:225-32.
120. Kuroda N, Shiotsu T, Hes O, et al. Acquired cystic disease-associated renal cell carcinoma with gain of chromosomes 3, 7, and 16, gain of chromosome X, and loss of chromosome Y. Med Mol Morphol 2010;43:231-4.
121. Kuntz E, Yusenko MV, Nagy A, et al. Oligoarray comparative genomic hybridization of renal cell tumors that developed in patients with acquired cystic renal disease. Hum Pathol 2010;41:1345-9.
122. Tajima S, Waki M, Doi W, et al. Acquired cystic disease-associated renal cell carcinoma with a focal sarcomatoid component: Report of a case showing more pronounced polysomy of chromosomes 3 and 16 in the sarcomatoid component. Pathol Int 2015;65:89-94.
123. Kiuru M, Launonen V, Hietala M, et al. Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. Am J Pathol 2001;159:825-9.
124. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002;30:406-10.
125. Barrisford GW, Singer EA, Rosner IL, et al. Familial renal cancer: molecular genetics and surgical management. Int J Surg Oncol 2011;2011:658767.
126. Lehtonen HJ. Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics. Fam Cancer 2011;10:397-411.
127. Grubb RL, 3rd, Franks ME, Toro J, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 2007;177:2074-9; discussion 9-80.
128. Sanz-Ortega J, Vocke C, Stratton P, et al. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome. Am J Surg Pathol 2013;37:74-80.
129. Merino MJ, Torres-Cabala C, Pinto P, et al. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 2007;31:1578-85.
130. Udager AM, Alva A, Chen YB, et al. Hereditary leiomyomatosis and renal cell carcinoma (HLRCC): a rapid autopsy report of metastatic renal cell carcinoma. Am J Surg Pathol 2014;38:567-77.
131. Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 2003;73:95-106.
132. Alam NA, Rowan AJ, Wortham NC, et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum Mol Genet 2003;12:1241-52.
133. Gardie B, Remenieras A, Kattygnarath D, et al. Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. J Med Genet 2011;48:226-34.
134. Isaacs JS, Jung YJ, Mole DR, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005;8:143-53.
135. Alderson NL, Wang Y, Blatnik M, et al. S-(2-Succinyl)cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate. Arch Biochem Biophys 2006;450:1-8.
136. Nagai R, Brock JW, Blatnik M, et al. Succination of protein thiols during adipocyte maturation: a biomarker of mitochondrial stress. J Biol Chem 2007;282:34219-28.
137. Frizzell N, Rajesh M, Jepson MJ, et al. Succination of thiol groups in adipose tissue proteins in diabetes: succination inhibits polymerization and secretion of adiponectin. J Biol Chem 2009;284:25772-81.
138. Joseph NM, Solomon DA, Frizzell N, et al. Morphology and Immunohistochemistry for 2SC and FH Aid in Detection of Fumarate Hydratase Gene Aberrations in Uterine Leiomyomas From Young Patients. Am J Surg Pathol 2015;39:1529-39.
139. Bardella C, El-Bahrawy M, Frizzell N, et al. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J Pathol 2011;225:4-11.
140. Chen YB, Brannon AR, Toubaji A, et al. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am J Surg Pathol 2014;38:627-37.
141. Jung SJ, Chung JI, Park SH, et al. Thyroid follicular carcinoma-like tumor of kidney: a case report with morphologic, immunohistochemical, and genetic analysis. Am J Surg Pathol 2006;30:411-5.
142. Sterlacci W, Verdorfer I, Gabriel M, et al. Thyroid follicular carcinoma-like renal tumor: a case report with morphologic, immunophenotypic, cytogenetic, and scintigraphic studies. Virchows Arch 2008;452:91-5.
143. Amin MB, Gupta R, Ondrej H, et al. Primary thyroid-like follicular carcinoma of the kidney: report of 6 cases of a histologically distinctive adult renal epithelial neoplasm. Am J Surg Pathol 2009;33:393-400.
144. Dhillon J, Tannir NM, Matin SF, et al. Thyroid-like follicular carcinoma of the kidney with metastases to the lungs and retroperitoneal lymph nodes. Hum Pathol 2011;42:146-50.
145. Alessandrini L, Fassan M, Gardiman MP, et al. Thyroid-like follicular carcinoma of the kidney: report of two cases with detailed immunohistochemical profile and literature review. Virchows Arch 2012;461:345-50.
146. Khoja HA, Almutawa A, Binmahfooz A, et al. Papillary thyroid carcinoma-like tumor of the kidney: a case report. Int J Surg Pathol 2012;20:411-5.
147. Malde S, Sheikh I, Woodman I, et al. Primary thyroid-like follicular renal cell carcinoma: an emerging entity. Case Rep Pathol 2013;2013:687427.
148. Chougule A, Bal A, Das A, et al. Thyroid-like follicular renal cell carcinoma: an emerging morphological variant. Pathology 2014;46:657-60.
149. Dhillon J, Mohanty SK, Krishnamurthy S. Cytologic diagnosis of thyroid-like follicular carcinoma of the kidney: a case report. Diagn Cytopathol 2014;42:273-7.
150. Ghaouti M, Roquet L, Baron M, et al. Thyroid-like follicular carcinoma of the kidney: a case report and review of the literature. Diagn Pathol 2014;9:186.
151. Lin YZ, Wei Y, Xu N, et al. Thyroid-like follicular carcinoma of the kidney: A report of two cases and literature review. Oncol Lett 2014;7:1796-802.
152. Vicens RA, Balachandran A, Guo CC, et al. Multimodality imaging of thyroid-like follicular renal cell carcinoma with lung metastases, a new emerging tumor entity. Abdom Imaging 2014;39:388-93.
153. Wu WW, Chu JT, Nael A, et al. Thyroid-like follicular carcinoma of the kidney in a young patient with history of pediatric acute lymphoblastic leukemia. Case Rep Pathol 2014;2014:313974.
154. Ohe C, Kuroda N, Pan CC, et al. A unique renal cell carcinoma with features of papillary renal cell carcinoma and thyroid-like carcinoma: a morphological, immunohistochemical and genetic study. Histopathology 2010;57:494-7.
155. Graux C, Cools J, Michaux L, et al. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia 2006;20:1496-510.
156. MacLennan GT, Farrow GM, Bostwick DG. Low-grade collecting duct carcinoma of the kidney: report of 13 cases of low-grade mucinous tubulocystic renal carcinoma of possible collecting duct origin. Urology 1997;50:679-84.
157. Azoulay S, Vieillefond A, Paraf F, et al. Tubulocystic carcinoma of the kidney: a new entity among renal tumors. Virchows Arch 2007;451:905-9.
158. Yang XJ, Zhou M, Hes O, et al. Tubulocystic carcinoma of the kidney: clinicopathologic and molecular characterization. Am J Surg Pathol 2008;32:177-87.
159. Amin MB, MacLennan GT, Gupta R, et al. Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma. Am J Surg Pathol 2009;33:384-92.
160. Zhou M, Yang XJ, Lopez JI, et al. Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification. Am J Surg Pathol 2009;33:1840-9.
161. Tran T, Jones CL, Williamson SR, et al. Tubulocystic renal cell carcinoma is an entity that is immunohistochemically and genetically distinct from papillary renal cell carcinoma. Histopathology 2015. [Epub ahead of print].
162. Osunkoya AO, Young AN, Wang W, et al. Comparison of gene expression profiles in tubulocystic carcinoma and collecting duct carcinoma of the kidney. Am J Surg Pathol 2009;33:1103-6.
163. Deshmukh M, Shet T, Bakshi G, et al. Tubulocystic carcinoma of kidney associated with papillary renal cell carcinoma. Indian J Pathol Microbiol 2011;54:127-30.
164. Chen N, Nie L, Gong J, et al. Gains of chromosomes 7 and 17 in tubulocystic carcinoma of kidney: two cases with fluorescence in situ hybridisation analysis. J Clin Pathol 2014;67:1006-9.
165. Hes O, Petersson F, Kuroda N, et al. Renal hybrid oncocytic/chromophobe tumors-a review. Histol Histopathol 2013;28:1257-64.
166. Abbosh PH, Grubb RL, 3rd, Cao D, et al. Hybrid renal tumors in Birt-Hogg-Dube syndrome. J Urol 2011;186:2413-4.
167. Adley BP, Smith ND, Nayar R, et al. Birt-Hogg-Dube syndrome: clinicopathologic findings and genetic alterations. Arch Pathol Lab Med 2006;130:1865-70.
168. Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol 2002;26:1542-52.
169. Mai KT, Dhamanaskar P, Belanger E, et al. Hybrid chromophobe renal cell neoplasm. Pathol Res Pract 2005;201:385-9.
170. Nagashima Y, Furuya M, Gotohda H, et al. FLCN gene-mutated renal cell neoplasms: mother and daughter cases with a novel germline mutation. Int J Urol 2012;19:468-70.
171. Petersson F, Gatalica Z, Grossmann P, et al. Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases. Virchows Arch 2010;456:355-65.
172. Delongchamps NB, Galmiche L, Eiss D, et al. Hybrid tumour 'oncocytoma-chromophobe renal cell carcinoma' of the kidney: a report of seven sporadic cases. BJU Int 2009;103:1381-4.
173. Gobbo S, Eble JN, Delahunt B, et al. Renal cell neoplasms of oncocytosis have distinct morphologic, immunohistochemical, and cytogenetic profiles. Am J Surg Pathol 2010;34:620-6.